Weill Cornell Medicine (WMC)’s Research Business Management unit (RBM) will manage all finances and administrative support for WCM’s proposed Autoimmunity Center of Excellence (ACE) and serve as the ACE Funds Management Core (AFMC). RBM is staffed by an experienced team of portfolio managers, each with a minimum of ten years of experience in pre and post award administration. The unit is flexible, adaptable and easily scalable to need. Its integration with central offices allows for maximum efficiencies in managing complex multisite awards, an ideal model for the AFMC. WCM and the RBM unit is fully committed to supporting legacy projects under the current Autoimmunity Centers of Excellence cycle and will work closely with the current AFMC to ensure a seamless transition of all projects under WCM’s AFMC. As needed, new agreements will be established between the WCM AFMC and participating sites to provide continuing support. Working in tandem with the WCM’s Office of Sponsored Research Administration, the WCM AFMC will initiate, negotiate and execute all subawards, service agreements and related contracts under the ACE Program. Using existing streamlined processes and systems, the WCM AFMC will expeditiously process and manage all agreements under the program with full transparency to all stakeholders. This will include tracking and reporting on agreement negotiations, sign off and financial activities. Budget, invoicing and reporting tools will be shared among the network and employed to streamline and standardize management across sites. WCM and the RBM unit is fully committed to supporting the ACE program with full transparency and accountability. The WCM led AFMC will submit formal quarterly reports to NIAID through the ACE program staff and prepare annual progress reports. The report format will include detailed financial data for each subcontract. We are committed to maintaining a strong line of communication between the AFMC, the ACE Steering Committee and NIAID.